

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BOREA ET AL.

Group Art Unit: 1614

Serial No.: 10/603,406

Examiner: Gembah, Shirley V.

Filed: June 24, 2003

Attorney Docket No.: PAT-0040-US-NP2

For: ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A₃
ANTAGONISTS

Mail Stop: Amendment

Conf. No.: 4184

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

RESPONSE TO NON-FINAL OFFICE ACTION

Sir:

This is in response to the Final Office action of August 24, 2007 on the above identified Application No. 10/603,406, filed June 24, 2003. The finality of the office action was however withdrawn by the Examiner in the Interview of October 15, 2007. The substance of the interview has been recorded in the PTOL-413 form, signed and dated October 21, 2007.

Please enter the following:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 5 of this paper.

It is estimated that no fees are required for filing this Amendment. Notwithstanding, if a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to King Pharmaceuticals Deposit Account No. 50-3706.